GlobalData on MSN
Pilatus Biosciences doses first patient in PLT012 antibody trial
The study will assess the tolerability, safety, maximum tolerated dose, and the recommended Phase II dose of PLT012.
A new review outlines design principles and applications of synthetic membraneless organelles built through liquid-liquid phase separation for use in biotechnology.
The mechanism of action of mRNA vaccines goes far beyond harnessing host cellular machinery to produce antigenic proteins to spur immunity, write Nicolas Hulscher, M.P.H., Peter A. McCullough, M.D., M ...
Ketogenic diet therapies, including the classic ketogenic diet, modified Atkins diet, and low glycaemic index treatment, have ...
First-in-human study underway evaluating anti-CD36 monoclonal antibody designed to restore metabolic fitness in exhausted T cells, reduce immunosuppressive cells, and enhance antitumor immunity Pilatu ...
Techno-Science.net on MSN
When sleep apnea puts metabolism on a different time zone
Sleep apnea affects nearly one billion people worldwide and causes repeated episodes of oxygen deprivation during the night, ...
Discover how fat cells, beyond mere storage, can be harnessed for innovative weight loss therapies through energy expenditure ...
For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...
Researchers at the University of Gothenburg have identified a protein linked to an increased risk of metastasis and recurrence in lung cancer. The findings are presented in a study published in the ...
Cancer biology increasingly recognizes that cancer stem cells (CSCs) represent a critical subpopulation within tumors, marked by their self-renewal, ...
Omics-driven insights into tumor microenvironment determinants of immunotherapy response in melanoma
Immunotherapy has revolutionized cancer treatment, yet response rates remain highly variable across tumor types and individual patients. Increasing evidence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results